Bupropion Hcl Er (xl) Tablet, Extended Release
NDC Package 70756-830-30

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Bupropion Hcl Er (xl) (bupropion hcl er) tablets is bupropion hydrochloride extended-release tablets (XL) are indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM). This formulation utilizes a tablet, extended release delivery system. Marketed by Lifestar Pharma Llc, this product is identified by NDC 70756-830 and is authorized under FDA application NDA022497.

Identification & Billing

NDC Package Code
70756-830-30
Package Description
30 TABLET, EXTENDED RELEASE in 1 BOTTLE
Product Code
70756-830
11-Digit Billing Format
70756083030
RxNorm Crosswalk
  • RxCUI: 1232585 - buPROPion HCl 450 MG 24HR Extended Release Oral Tablet
  • RxCUI: 1232585 - 24 HR bupropion hydrochloride 450 MG Extended Release Oral Tablet
  • RxCUI: 1232585 - bupropion hydrochloride 450 MG 24 HR Extended Release Oral Tablet

Clinical Specifications

Proprietary Name
Bupropion Hcl Er (xl)
Non-Proprietary Name
Bupropion Hcl Er
Substance Name
Bupropion Hydrochloride
Dosage Form
Tablet, Extended Release - A solid dosage form containing a drug which allows at least a reduction in dosing frequency as compared to that drug presented in conventional dosage form.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
BUPROPION HYDROCHLORIDE 450 mg/1
Pharmacologic Class
Usage Information
Bupropion hydrochloride extended-release tablets (XL) are indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM). The efficacy of the immediate-release formulation of bupropion was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult patients with MDD. The efficacy of the sustained-release formulation of bupropion in the maintenance treatment of MDD was established in a long-term (up to 44 weeks), placebo-controlled trial in patients who had responded to bupropion in an 8-week study of acute treatment [see Clinical Studies (14)]. The physician who elects to use bupropion hydrochloride extended-release tablets (XL) for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient.

Regulatory & Marketing

Labeler Name
Lifestar Pharma Llc
Product Type
Human Prescription Drug
FDA Application #
NDA022497
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
05-01-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (70756-830). Click a package code to view its specific billing and regulatory data.

70756-830-16
16000 TABLET, EXTENDED RELEASE in 1 BOX

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70756-830-30 identifies a specific commercial package of 30 tablet, extended release in 1 bottle of Bupropion Hcl Er (xl), a human prescription drug labeled by Lifestar Pharma Llc. This tablet, extended release is formulated for oral use and contains bupropion hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Lifestar Pharma Llc on May 01, 2026. The current certification is valid through December 31, 2027.

How is this Lifestar Pharma Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70756083030. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
70756-830-30
11-Digit CMS (5-4-2)
70756-0830-30

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.